Alissa J. Cooper, MD

Panelists discuss how durvalumab consolidation after chemoradiation has become the standard of care for limited-stage SCLC based on the ADRIATIC trial, with most patients being considered candidates for the 2-year treatment course.

Isabel Preeshagul, DO, MBS, and colleagues share updates from across the lung cancer space as discussed in a recent State of the Science Summit.

Alissa J. Cooper, MD, discusses insights from the TROPION-Lung01 trial that may help guide antibody-drug conjugate use in second-line NSCLC.